Connect
Discussion
Comment receiving replies
Replies to "Right now the radiotherapy ligand drugs are reserved for hormone insensitive patients. It had only recently..."
Prostate Cancer | Last Active: 1 hour ago | Replies (9)
Comment receiving replies
Right now the radiotherapy ligand drugs are reserved for hormone insensitive patients. It had only recently been reserved for chemotherapy treated hormone insensitive patients. I suspect the next notch down will be for those who are still sensitive to hormone treatment. Who knows that class of drugs may become first line treatment in the not too distant future? Pluvicto (PSMA Lutetium-177) is the current first approved drug in that class. A number of variants are in the pipeline, The 'over the horizon' radar is reassuring for any one on the 'PC disease spectrum.'
Replies to "Right now the radiotherapy ligand drugs are reserved for hormone insensitive patients. It had only recently..."
Connect
That makes sense. ARSIs were also originally approved only for castrate-resistant cancer, but some of them were later extended to mCSPC as the result of trials like TITAN showing huge benefits.
I think that's part of a bigger shift in metastatic prostate-cancer treatment from the old-school "try one thing until it fails, then move to the next" to the new, emerging best practice "hit it early, hit it hard".